Page 46 - AIH-2-2
P. 46

Artificial Intelligence in Health                                         New drug discovery in the AI era



               doi: 10.1016/j.eng.2022.04.021                  43.  Atas Guvenilir H, Doğan T. How to approach machine
                                                                  learning-based prediction of drug/compound-target
            32.  Tran TTV, Surya Wibowo A, Tayara H, Chong KT. Artificial
               intelligence in drug toxicity prediction: Recent advances,   interactions. J Cheminform. 2023;15(1):16-36.
               challenges, and future perspectives.  J  Chem Inf Model.      doi: 10.1186/s13321-023-00689-w
               2023;63(9):2628-2643.
                                                               44.  Sarker IH. Deep learning: A  comprehensive overview on
               doi: 10.1021/acs.jcim.3c00200                      techniques, taxonomy, applications and research directions.
            33.  Lin Z, Chou WC. Machine learning and artificial intelligence   SN Comput Sci. 2021;2:420.
               in toxicological sciences. Toxicol Sci. 2022;189(1):7-19.     doi: 10.1007/s42979-021-00815-1
               doi: 10.1093/toxsci/kfac075                     45.  Lin X. DeepGS: Deep representation learning of graphs and
            34.  Askin S, Burkhalter D, Calado G, El Dakrouni S. Artificial   sequences for drug-target binding affinity prediction. arXiv.
               intelligence applied to clinical trials: Opportunities and   2020.
               challenges. Health Technol (Berl). 2023;13(2):203-213.     doi: 10.48550/arXiv.2003.13902
               doi: 10.1007/s12553-023-00738-2                 46.  Öztürk H, Özgür A, Ozkirimli E. DeepDTA: Deep
            35.  Vo  TH,  Nguyen  NTK,  Le  NQK.  Improved  prediction   drug-target binding affinity prediction.  Bioinformatics.
               of drug-drug interactions using ensemble deep neural   2018;34(17):i821-i829.
               networks. Med Drug Discov. 2023;17:100149.         doi: 10.1093/bioinformatics/bty593
               doi: 10.1016/j.medidd.2022.100149               47.  Thafar MA, Alshahrani M, Albaradei S, Gojobori T,
            36.  Pun FW, Ozerov IV, Zhavoronkov A. AI-powered therapeutic   Essack  M, Gao X. Affinity2Vec: Drug-target binding affinity
               target discovery. Trends Pharmacol Sci. 2023;44(9):561-572.  prediction through representation learning, graph mining,
                                                                  and machine learning. Sci Rep. 2022;12(1):4751.
               doi: 10.1016/j.tips.2023.06.010
                                                                  doi: 10.1038/s41598-022-08787-9
            37.  Vitali E, Ficarelli F, Bisson M,  et al. GPU-optimized
               approaches to molecular docking-based virtual screening   48.  Powers AS, Yu HH, Suriana P,  et al. Geometric deep
               in drug discovery: A comparative analysis. J Parallel Distrib   learning for structure-based ligand design.  ACS Cent Sci.
               Comput. 2024;186:104819.                           2023;9(12):2257-2267.
               doi: 10.1016/j.jpdc.2023.104819                    doi: 10.1021/acscentsci.3c00572
            38.  Santos-Martins D, Solis-Vasquez L, Tillack AF, Sanner   49.  Askr H, Elgeldawi E, Aboul Ella H, Elshaier YA, Gomaa  MM,
               MF, Koch A, Forli S. Accelerating AutoDock4 with GPUs   Hassanien AE. Deep learning in drug discovery: An
               and gradient-based  local  search.  J  Chem Theory Comput.   integrative  review  and  future  challenges.  Artif Intell Rev.
               2021;17(2):1060-1073.                              2023;56(7):5975-6037.
               doi: 10.1021/acs.jctc.0c01006                      doi: 10.1007/s10462-022-10306-1
            39.  Jumper  J,  Evans  R,  Pritzel A,  et  al.  Highly accurate protein   50.  Zhavoronkov A, Ivanenkov YA, Aliper A,  et  al. Deep
               structure prediction with AlphaFold. Nature. 2021;596:583-589.  learning enables rapid identification of potent DDR1 kinase
                                                                  inhibitors. Nat Biotechnol. 2019;37:1038-1040.
               doi: 10.1038/s41586-021-03819-2
                                                                  doi: 10.1038/s41587-019-0224-x
            40.  Díaz-Rovira AM, Martín H, Beuming T, Díaz L, Guallar  V,
               Ray SS. Are deep learning structural models sufficiently   51.  Hargrave-Thomas  E,  Yu  B,  Reynisson  J.  Serendipity  in
               accurate for virtual screening? Application of docking   anticancer drug discovery. World J Clin Oncol. 2012;3(1):1-6.
               algorithms to AlphaFold2 predicted structures. J Chem Inf      doi: 10.5306/wjco.v3.i1.1
               Model. 2023;63:1668-1674.
                                                               52.  Dwivedi YK, Kshetri N, Hughes L, et al. Opinion Paper: “So
               doi: 10.1021/acs.jcim.2c01270                      what if ChatGPT wrote it?” Multidisciplinary perspectives
            41.  Yang Z, Zeng X, Zhao Y, Chen R. AlphaFold2 and its   on opportunities, challenges and implications of generative
               applications in the fields of biology and medicine.  Signal   conversational AI for research, practice and policy. Int J Inf
               Transduct Target Ther. 2023;8:115.                 Manag. 2023;71:102642.
               doi: 10.1038/s41392-023-01381-z                    doi: 10.1016/j.ijinfomgt.2023.102642
            42.  Yang H, Sun L, Li W, Liu G, Tang Y. Corrigendum:  In   53.  Jayatunga MK, Ayers M, Bruens L, Jayanth D, Meier C.
               silico prediction of chemical toxicity for drug design using   How successful are AI-discovered drugs in clinical trials?
               machine learning methods and structural alerts. Front   A first analysis and emerging lessons. Drug Discov Today.
               Chem. 2018;6:129.                                  2024;29(6):104009.
               doi: 10.3389/fchem.2018.00129                      doi: 10.1016/j.drudis.2024.104009

            Volume 2 Issue 2 (2025)                         40                               doi: 10.36922/aih.4423
   41   42   43   44   45   46   47   48   49   50   51